Wave Life Sciences Secures FDA Alignment for Streamlined WVE-006 Trial in AATD

  • Wave Life Sciences plans a single, two-year registrational trial for WVE-006 with a one-year interim analysis for potential accelerated approval.
  • FDA supports the use of Wave’s LC-MS assay to measure M-AAT and Z-AAT proteins for the WVE-006 program.
  • WVE-006 is designed to address both lung and liver manifestations of AATD with infrequent subcutaneous dosing.
  • The ongoing Phase 1b/2a RestorAATion-2 trial data for the 600 mg (monthly) multidose cohort is expected in Q4 2026.

Wave Life Sciences’ alignment with the FDA on the registrational pathway for WVE-006 underscores the growing interest in RNA editing therapies for rare genetic disorders. The streamlined trial design could set a precedent for other biotech companies developing similar treatments, potentially reducing the time and cost of bringing innovative therapies to market. The focus on AATD, a condition with significant unmet medical needs, highlights the strategic importance of targeting rare diseases with high-impact therapies.

Regulatory Efficiency
Whether the streamlined trial design will accelerate WVE-006’s path to market and reduce development costs.
Clinical Efficacy
The pace at which interim data from the RestorAATion-2 trial will demonstrate WVE-006’s safety and efficacy.
Market Potential
How WVE-006’s potential to address both lung and liver manifestations of AATD will position it against existing therapies.